Efficacy of moxidectin against gastrointestinal nematode infections in sheep

Moxidectin use in Scottish sheep flocks suggests a need for clearer product labelling and communication of updated SCOPS guidelines

BACKGROUND

Guidelines for sustainable use of moxidectin were established in 2020. This study aimed to identify how Scottish sheep farmers are using this key endectocide and estimate its effectiveness against gastrointestinal nematodes.

METHODS

Questionnaires were distributed to sheep farmers across Scotland, and analysis focused on moxidectin use in relation to Sustainable Control of Parasites in Sheep (SCOPS) guidelines. Farmers using moxidectin in their flock volunteered to submit post-treatment sheep faecal samples, which were analysed for the presence of gastrointestinal nematodes using faecal egg counts with polymerase chain reaction to determine species.

RESULTS

Despite 70% of farmers using moxidectin in 2020, knowledge levels varied: 24% of farmers included other anthelmintics when asked about moxidectin use. Moxidectin was used for a wide variety of reasons, and most farmers did not consistently follow SCOPS guidelines. Despite only 2 of 76 farmers reporting failure of moxidectin treatment, gastrointestinal nematodes were found following moxidectin treatment on five out of six farms tested and included Teladorsagia circumcincta, Cooperia curticei, Haemonchus contortus and Nematodirus sp.

CONCLUSION

Findings from this project indicate the need for improved anthelmintic product labelling and farmer support to encourage sustainable use. The presence of nematodes in treated animals is suggestive of anthelmintic resistance.

Efficacy of moxidectin 1% injectable and 0.2% oral drench against natural infection by Dictyocaulus filaria in sheep

Two separate trials (I and II) with 34 and 32 Churra ewes, respectively, and distributed into two groups, have been carried out to evaluate the efficacy of two different formulations of moxidectin at a dose rate of 0.2mg/kg body weight (b.w.) against natural infection by Dictyocaulus filaria in sheep. Trial I was designed to evaluate a 1% moxidectin injectable formulation, whereas in trial II a 0.2% moxidectin oral drench formulation was used. The efficacy was measured on the basis of the reduction of the faecal larval counts and of adult worm recoveries at slaughter. In each trial, a group of animals was treated on day 0 with moxidectin 1% injectable or moxidectin 0.2% oral drench and the other group acted as untreated control. When the faecal larval counts was compared within the treated groups, the efficacy was over 95% until day +13, and 100% at the remainder of the sampling dates after the application of injectable moxidectin, whereas in trial II, the larvae per gram (lpg) of faeces increased until the first sampling time post treatment (p.t.), day +6, and zero counts were recorded for all animals by the following days. On the basis of adult worm recoveries at necropsy, the efficacy of the treatment was 100% in both trials, however, adult worms were detected at slaughter for all control sheep. These results indicate that moxidectin 1% injectable and moxidectin 0.2% oral drench, administered at 0.2mg/kg b.w., were 100% effective against D. filaria infection in sheep. No adverse reactions to the treatments were observed in the animals.

Determination of moxidectin in plasma by high-performance liquid chromatography with automated solid-phase extraction and fluorescence detection

Moxidectin is a newly developed potent anthelmintic agent with a high potency although present at very low concentration in cattle plasma. A method is described for the determination of moxidectin in plasma using high-performance liquid chromatography with fluorescence detection (excitation and emission wavelengths 383 and 447 nm, respectively). The fluorescent derivative was obtained by a dehydrative reaction with trifluoroacetic anhydride and N-methylimidazole. The method employs 1-ml plasma samples and has linear calibration graphs (r = 0.997) over the concentration range studied, i.e., 0.1-10 ng/ml. Solid-phase extraction using the Benchmate procedure was used for sample preparation. Recoveries at low concentrations (0.1-10 ng/ml) were higher than 75%. The limit of quantification was 0.1 ng/ml (C.V. 6.95%). The method is suitable for the pharmacokinetic study of moxidectin after subcutaneous administration to cows.